Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.

@article{Tsang2014ImmunogenicityAS,
  title={Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.},
  author={Peter H Tsang and Geoffrey J Gorse and Cynthia B Strout and Malcolm Sperling and David P. Greenberg and Ayca Ozol-Godfrey and Carlos A Diazgranados and Victoria A Landolfi},
  journal={Vaccine},
  year={2014},
  volume={32 21},
  pages={2507-17}
}
We conducted a randomized, controlled, multicenter, phase II study to evaluate the immunogenicity and safety of an investigational intradermal (ID) trivalent influenza vaccine (TIV) and a high-dose (HD) intramuscular (IM) TIV in older adults (≥65 years of age). Older adult subjects were immunized with ID vaccine containing either 15μg hemagglutinin (HA)/strain (n=636) or 21μg HA/strain (n=634), with HD IM vaccine containing 60μg HA/strain (n=320), or with standard-dose (SD) IM vaccine (Fluzone… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Transcutaneous vaccination via laser microporation

Journal of controlled release : official journal of the Controlled Release Society • 2012

Similar Papers

Loading similar papers…